Evidence map›Paper›PMID 34369869›Full record

SynthesisBlood transfusion = Trasfusione del sangue2022

Autoimmune disorders of platelet function: systematic review of cases of acquired Glanzmann thrombasthenia and acquired delta storage pool disease.

Monica Bacci, Antonietta Ferretti, Marina Marchetti, Maria A Alberelli, Anna Falanga, Corrado Lodigiani, Erica De Candia

Open access · greenAbstract readSystematic Review
In one paragraph

Synthesis in Blood transfusion = Trasfusione del sangue, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Platelet function abnormalities in acquired hemophilia A.Research and practice in thrombosis and haemostasis · 2026
    Article
  3. Review
  4. Article
  5. Novel homozygous silent mutation ofFrontiers in pediatrics · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Monica BacciThrombosis and Haemorrhagic Diseases Unit, Humanitas Clinical and Research Center IRCCS, Rozzano (MI), Italy.
Antonietta FerrettiHaemorrhagic and Thrombotic Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy.
Marina MarchettiDepartement of Immunohaematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy.
Maria A AlberelliHaemorrhagic and Thrombotic Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy.
Anna FalangaDepartement of Immunohaematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy.
Corrado LodigianiThrombosis and Haemorrhagic Diseases Unit, Humanitas Clinical and Research Center IRCCS, Rozzano (MI), Italy.
Erica De CandiaThrombosis and Haemorrhagic Diseases Unit, Humanitas Clinical and Research Center IRCCS, Rozzano (MI), Italy.
Agostino Gemelli University Polyclinic · ITHumanitas University · ITOspedale Papa Giovanni XXIII · ITUniversità Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acquired platelet function disorders (PFD) are rare bleeding diseases that should be suspected in all patients with unexplained mucocutaneous bleedings of recent onset, with no previous history of haemorrhages, and with normal coagulation test and platelet count. Drug-induced platelet function bleeding disorders are the most frequent PFDs and can easily be identified on the basis of recent administration of platelet-inhibiting drugs. Apart from these, the most challenging acquired PFDs are those caused by autoimmune mechanisms. In fact, demonstration of autoantibodies inhibiting platelet function may be difficult in most non-specialised centres. Among autoimmune PFDs (aPFDs), acquired Glanzmann thrombasthenia (aGT), which is caused by autoantibodies that bind to platelet αIIbβ3 integrin, inhibiting its function, is the most frequent. aGT can be associated with underlying haematological malignancies or autoimmune diseases but can also be idiopathic. More rarely, other immune-mediated PFDs can occur, such as acquired delta storage pool disease (aδSPD). Treatment of aPFDs must rely on the control of acute and chronic bleedings, treatment of the underlying disease in secondary forms, and immunosuppressive treatment for autoantibody reduction or eradication. aPFDs may completely resolve upon treatment of any underlying disease that may be present. In primary aPFDs, and in the majority of secondary forms, treatment relies on immunosuppressive therapies.Here we present a systematic review of previously described immune-mediated aGT and aδSPD cases. Clinical and laboratory characteristics, treatments for the control of bleedings and for the eradication of autoantibodies, and responses to treatments are also discussed. Although no guidelines are available for the management of these very rare conditions, presentation of all cases reported so far can help clinicians in the diagnosis and treatment of these life-threatening diseases.

Indexed as

Autoimmune DiseasesThrombastheniaAlbinismAutoantibodiesHemorrhagic DisordersHermanski-Pudlak SyndromeHumansPlatelet Glycoprotein GPIIb-IIIa ComplexAutoantibodiesPlatelet Glycoprotein GPIIb-IIIa Complex

Identifiers

PMID34369869
PMCPMC9480966
OpenAlexW3188939837

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.